Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

References

• Gadgeel SM, Ramalingam SS, Kalemkerian GP. Treatment of lung cancer. Radiol Clin North Am 2012; 50:961 - 74; http://dx.doi.org/10.1016/j.rcl.2012.06.003; PMID: 22974781
   PubMed Web of Science ®Google Scholar
• RTOG 0839: Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/− Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer.
   Google Scholar
• Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, Garcia C, Giner V, Holbrechts S, Lafitte JJ, et al, ELCWP. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39:9 - 28; http://dx.doi.org/10.1183/09031936.00190310; PMID: 21737547
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19:92 - 8; http://dx.doi.org/10.1093/annonc/mdm399; PMID: 17785764
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191; PMID: 16618717
   PubMed Web of Science ®Google Scholar
• Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30:3570 - 7; http://dx.doi.org/10.1200/JCO.2012.42.2592; PMID: 22734028
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Ferrara ML, Rossi A. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 2009; 14:601 - 11; http://dx.doi.org/10.1634/theoncologist.2008-0153; PMID: 19482958
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626 - 34; http://dx.doi.org/10.1200/JCO.2007.14.7116; PMID: 18316791
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486:537 - 40; PMID: 22722843
   PubMed Web of Science ®Google Scholar
• Soulières D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao MS, Kamel-Reid S. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol 2010; 17:Suppl 1 S31 - 40; PMID: 20680106
   PubMedGoogle Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010; 28:4769 - 77; http://dx.doi.org/10.1200/JCO.2009.27.4365; PMID: 20921461
   PubMed Web of Science ®Google Scholar
• Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 2013; 4:15; http://dx.doi.org/10.3389/fphar.2013.00015; PMID: 23407898
   PubMed Web of Science ®Google Scholar
• Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28:744 - 52; http://dx.doi.org/10.1200/JCO.2009.24.3030; PMID: 20038723
   PubMed Web of Science ®Google Scholar
• Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 2012; 72:Suppl 1 28 - 36; http://dx.doi.org/10.2165/1163012-S0-000000000-00000; PMID: 22712795
   PubMedGoogle Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567 - 78; http://dx.doi.org/10.1056/NEJMoa053422; PMID: 16467544
   PubMed Web of Science ®Google Scholar
• Gottschling S, Penzel R, Pelz T, Herpel E, Schnabel PA, Dyckhoff G, Thomas M, Kuhnt T. KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature. J Clin Oncol 2011; 29:e616 - 9; http://dx.doi.org/10.1200/JCO.2011.34.5892; PMID: 21555681
   PubMedGoogle Scholar
• Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol 2004; 14:639 - 47; http://dx.doi.org/10.1016/j.tcb.2004.09.014; PMID: 15519853
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424 - 30; http://dx.doi.org/10.1038/nature04869; PMID: 16724053
   PubMed Web of Science ®Google Scholar
• Minjgee M, Toulany M, Kehlbach R, Giehl K, Rodemann HPK-RAS. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys 2011; 81:1506 - 14; http://dx.doi.org/10.1016/j.ijrobp.2011.05.057; PMID: 21985943
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol 2013; 31:1112 - 21; http://dx.doi.org/10.1200/JCO.2012.43.0454; PMID: 23401440
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351 - 6; http://dx.doi.org/10.1038/nm.1890; PMID: 19029981
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; 31:2173 - 81; http://dx.doi.org/10.1200/JCO.2012.48.1390; PMID: 23630215
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, Rosell R. KRAS mutations in lung cancer. Clin Lung Cancer 2013; 14:205 - 14; http://dx.doi.org/10.1016/j.cllc.2012.09.007; PMID: 23122493
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883 - 92; http://dx.doi.org/10.1056/NEJMoa1113205; PMID: 22397650
   PubMed Web of Science ®Google Scholar